Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Sun Pharmaceutical Industries Limited | Zhejiang Hangyu Pharmaceutical Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Sun Pharmaceutical Industries Limited | Zhejiang Hangyu Pharmaceutical Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ODOMZO (sonidegib) works by inhibiting a molecular pathway, known as the hedgehog signaling pathway, which is indicated for the treatment of adult patients with locally advanced basal cell carcinoma.
Product Name : Odomzo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2020
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2014
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2014
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2014
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2014
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2014
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2013
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of LY2940680 in Japanese Participants With Advanced Cancers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2013
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2013
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable